Keyword: CMS

It's no secret that drug prices are higher in the U.S. than in other countries, and now the Trump administration appears poised to act.

Here's what to watch, now that the Trump administration has set in motion new rules that would require list prices in drug advertising.

After a CMS rule change in August, UnitedHealthcare is introducing step therapy in Medicare Advantage plans to favor biosimilars over certain brands.

The Senate voted in favor of drug pricing in DTC ads, while HHS works on a transparency proposal for Medicare and Medicaid.

Federal officials unveiled changes to Medicare Part B this week that could result in lower sales for Amgen and Regeneron.

CMS has pulled the plug on a plan to implement indication-specific pricing on Novartis' CAR-T drug Kymriah.

As federal drug pricing moves have floundered, state officials got busy. But Massachusetts is discovering there's a limit to drug-pricing innovation.

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's requested add-on payment.

Amid a particularly severe flu season, FDA chief Scott Gottlieb said the "holy grail" of vaccines—a shot that fights any strain of virus—is years off.

Sick of dealing with generic drug shortages and price increases, five large U.S. health systems are forming their own drugmaker.